Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Duloxetine Boehringer Ingelheim
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Duloxetine Boehringer Ingelheim is a small molecule serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of diabetic peripheral neuropathic pain (DPNP) in adults. It works by potentiation of serotonergic and noradrenergic activity in the central nervous system through the inhibition of the serotonin (5-HT) and norepinephrine (NE) transporters. This mechanism modulates descending inhibitory pain pathways, providing analgesic effects in neuropathic conditions. Originally developed by Eli Lilly and marketed as Cymbalta, this specific formulation was authorized for marketing by Boehringer Ingelheim in the European Union in 2008. It is typically administered orally at doses of 60 mg to 120 mg daily, often in gastro-resistant capsule form to prevent degradation in the stomach.
- Brand names
- Duloxetine Boehringer Ingelheim
- Other names
- duloxetineduloxetine hydrochloride
02
Targets
NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on Duloxetine Boehringer Ingelheim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Duloxetine Boehringer Ingelheim.